

CELGENE CORP /DE/  
Form 8-K  
April 21, 2008



**ITEM 8.01 OTHER EVENTS**

On April 21, 2008, Celgene International Sarl announced that Thalidomide Pharmion has been granted full marketing authorization by the European Commission for use in combination with melphalan and prednisone as a treatment for patients with newly diagnosed multiple myeloma. Multiple myeloma is the second most commonly diagnosed blood cancer. According to the International Myeloma Foundation, there are an estimated 750,000 people with multiple myeloma worldwide. There are more than 85,000 men and women in Europe currently undergoing treatment for multiple myeloma, and 25,000 people are expected to die from this blood cancer in 2008.

Attached hereto and incorporated herein by reference as Exhibit 99.1 is the Press Release announcing such information.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

Exhibit 99.1 Press Release dated April 21, 2008

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELGENE CORPORATION**

Date: April 21, 2008

By: /s/ David W. Gyska  
Name: David W. Gyska  
Title: Senior Vice President and  
Chief Financial Officer